Boundless Bio, Inc.
BOLD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782303
In the last 90 days, Boundless Bio, Inc. insiders filed 5 open-market purchases and 1 sale; 40 institutions reported holding it in 13F filings for Q2 2026, worth $38.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:16 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 27, 2025 |
| Operating expenses | $63.6M | $73.3M |
| Research and development | $44.8M | $55.3M |
| Selling, general and administrative | $18.7M | $18.0M |
| Operating income | -$63.6M | -$73.3M |
| Income tax | $0 | – |
| Net income | -$58.2M | -$65.4M |
| EPS, basic | $-2.60 | $-3.85 |
| EPS, diluted | $-2.60 | $-3.85 |
| Weighted shares, basic | 22.4M | 17.0M |
| Weighted shares, diluted | 22.4M | 17.0M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 27, 2025 |
| Cash and equivalents | $17.9M | $26.6M |
| Short-term investments | $89.7M | $125.5M |
| Total current assets | $109.6M | $154.4M |
| Property, plant and equipment | $3.22M | $4.32M |
| Total assets | $157.1M | $206.4M |
| Accounts payable | $1.49M | $1.27M |
| Total current liabilities | $12.5M | $8.13M |
| Total liabilities | $58.4M | $55.8M |
| Shareholders' equity | $98.7M | $150.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 27, 2025 |
| Operating cash flow | -$46.7M | -$60.8M |
| Capital expenditures | $546.0K | $2.54M |
| Free cash flow | -$47.2M | -$63.4M |
| Depreciation and amortization | $1.25M | $1.09M |
| Stock-based compensation | $6.13M | $7.52M |
| Investing cash flow | $37.8M | -$26.1M |
| Financing cash flow | $141.0K | $89.8M |
| Net change in cash | -$8.72M | $2.88M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 23.6M | +5.5% | SEC |
| Aug 5, 2026 | 22.7M | +1.6% | SEC |
| May 5, 2026 | 22.5M | +0.4% | SEC |
| Mar 2, 2026 | 22.4M | +0.5% | SEC |
| Oct 31, 2025 | 22.4M | +0.4% | SEC |
| Jul 31, 2025 | 22.4M | +0.6% | SEC |
| May 6, 2025 | 22.4M | +0.6% | SEC |
| Mar 21, 2025 | 22.3M | +0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.